Αρχική World News PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or... World News PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma Από Ogkologos - 9 Φεβρουαρίου, 2026 326 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Elections 2021: What the results mean for people with cancer 11 Μαΐου, 2021 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... 16 Σεπτεμβρίου, 2024 Maximizing the Prospects for Progress Against Cancer 11 Ιουνίου, 2018 Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers 19 Οκτωβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started Texting May Help Reduce Disparities in Colorectal Cancer Screening Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy...